Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma (MEPI-AGE)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Enrolling

Conditions: Hodgkin Lymphoma in Remission

Treatments: Other: peripheral blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT06761274

PR 1/CS/AIL/21 (Other Grant/Funding Number)

RC-2022-2773333 (Other Grant/Funding Number)

MEPI-AGE

Details and patient eligibility

About

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

• in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
• newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

Full description

The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
• Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
• Patients of both sexes aged ≥ 18 years at enrollment
• Signature of informed consent

Exclusion criteria

• Concomitant second neoplasm

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

Experimental group

Description:

in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV

Treatment:

Other: peripheral blood sampling